Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Status:
Completed
Trial end date:
2017-07-21
Target enrollment:
Participant gender:
Summary
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability
of AVP-786 as an adjunctive treatment compared with placebo in patients with residual
schizophrenia.